A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL.
Gatti-Mays ME, et al. Among authors: strauss j.
Clin Cancer Res. 2019 Aug 15;25(16):4933-4944. doi: 10.1158/1078-0432.CCR-19-0183. Epub 2019 May 20.
Clin Cancer Res. 2019.
PMID: 31110074
Free PMC article.